(Q36963184)

17 August 2017

1 reference

title

Mechanism of action of glatiramer acetate in treatment of multiple sclerosis (English)

1 reference

17 August 2017

0 references

Martin S Weber

1

1 reference

17 August 2017

Reinhard Hohlfeld

series ordinal

2

1 reference

17 August 2017

Scott S Zamvil

series ordinal

3

1 reference

17 August 2017

1 October 2007

1 reference

17 August 2017

1 reference

17 August 2017

4

1 reference

17 August 2017

647-653

1 reference

17 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1016/j.nurt.2007.08.002

17 August 2017

0 references

cites work

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Mechanisms of action of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Molecular requirements involved in suppression of eae by synthetic basic copolymers of amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Defective regulatory and effector T cell functions in patients with FOXP3 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Multiple immuno-regulatory defects in type-1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Amelioration of experimental colitis by Copaxone is associated with class-II-restricted CD4 immune blocking

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.08.002

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

12 December 2020

Multiple sclerosis: trial of a synthetic polypeptide

1 reference

12 December 2020

Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE)

1 reference

12 December 2020

Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.

1 reference

12 December 2020

T-lymphocyte entry into the central nervous system

1 reference

12 December 2020

Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease

1 reference

12 December 2020

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

1 reference

12 December 2020

Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses

1 reference

12 December 2020

Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules

1 reference

12 December 2020

Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis

1 reference

12 December 2020

Copolymer 1 inhibits experimental autoimmune uveoretinitis

1 reference

12 December 2020

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1

1 reference

12 December 2020

10.1016/J.NURT.2007.08.002

Identifiers

DOI

1 reference

Dimensions Publication ID

17 August 2017

0 references

0 references

1 reference